TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22432105
Drug: Insulin therapy
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapy initiated in 855 patients
Study: 24648482
Drug: Intraperitoneal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal lidocaine administration (IP)
Study: 24648482
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine infusion (IV)
Study: 4014870
Drug: Intermittent heavy
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent heavy exercise (VE, 68 L/min) lasting 14 min every 30 min during exposure
Study: 9527747
Drug: Low-dose opioid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose opioid anaesthesia (thoracic epidural analgesia combined with inhalational anaesthesia)
Study: 1461782
Drug: Vaccine containing
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine containing the strains Edmonston‐Zagreb, Rubini and Wistar Ra 27/3
Study: 3528718
Drug: Postoperative human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative human albumin administration
Study: 20561115
Drug: Individually tailored
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individually tailored oral health educational programme (ITOHEP)
Study: 3925430
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (C(OAc‐) and C(OAc+))
Study: 9226738
Drug: Self-administration behavior
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administration behavior
Study: 8062954
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) and hMG
Study: 29529919
Drug: Kinect-based VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kinect-based VR training + Physical Therapy (PT)
Study: 26866933
Drug: Transanal submucosal
Normalized name: mepivacaine
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transanal submucosal injection of polyacrylamide hydrogel
Study: 23642377
Drug: Ranibizumab (monthly)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (monthly)
Study: 28973227
Drug: Early resuscitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early resuscitation protocol for sepsis (n=107) including intravenous fluid bolus administration, vasopressors targeting mean arterial pressure (≥65 mm Hg), and blood transfusion for hemoglobin <7 g/dL.
Study: 9669827
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg twice daily via the Diskhaler (DH)
Study: 27434314
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate once-monthly (PP1M) injectable
Study: 26400458
Drug: Vercirnon 500
Normalized name: Vercirnon
DrugBank: Vercirnon (DB15250)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vercirnon 500 mg once daily
Study: 12629090
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist triptorelin (GnRHa) plus calcium supplementation
Study: 12629090
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist triptorelin (GnRHa)
Study: 22978595
Drug: Turmeric rhizome
Normalized name: Turmeric Rhizome (Curcuma Longa)
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turmeric rhizome powder (TRP) 0 g/kg (Control)
Study: 27743396
Drug: Crestal implants
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal implants placed at bone level
Study: 24295556
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 μg BD
Study: 31299774
Drug: Ridge-split technique
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridge-split technique with horizontal augmentation using autogenous bone graft
Study: 31299774
Drug: Ridge-split method
Normalized name: BLUE RIDGE BLUEBERRY
DrugBank: Blueberry (DB10629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ridge-split method with simultaneous implant placement
Study: 20023215
Drug: Sequential rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential rituximab (375 mg/m2) after completion of all chemotherapy
Study: 3019375
Drug: Cilazapril 10
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 10 mg
Study: 17370498
Drug: Seeds of
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seeds of Brassica Alb (0.01 g each point)
Study: 28051798
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) monotherapy
Study: 27042281
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec (IDeg)
Study: 9136839
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA, 750 mg/day)
Study: 18272319
Drug: Ketalar (ketamine)
Normalized name: ketamine Injectable Solution [Ketalar]
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketalar (ketamine) administered at induction until the end of surgery
Study: 15945402
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (400 IU daily)
Study: 26519688
Drug: Shuanghua Baihe
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shuanghua Baihe tablets
Study: 15805377
Drug: Naloxone hydrochloride
Normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone hydrochloride 0.01 mg/kg administered intravenously before oral administration of 1 mL of 30% glucose
Study: 2523665
Drug: Isradipine (monotherapy)
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine (monotherapy)
Study: 9236562
Drug: Nizatidine 225
Normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizatidine 225 mg
Study: 28277352
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate (25 mg every 8 hours) plus intravenous infusion of 2 L isotonic solution
Study: 28049170
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (500 µg twice daily) for 30 months
Study: 10029609
Drug: Mesalamine microgranular
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine microgranular preparation, 4 g
Study: 8296092
Drug: CVD 103-HgR
Normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103-HgR vaccine
Study: 29070637
Drug: Active photobiomodulation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active photobiomodulation therapy (PBMT)
Study: 23856779
Drug: Deleobuvir 400
Normalized name: Deleobuvir
DrugBank: Deleobuvir (DB14850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deleobuvir 400 mg q8h for 5 days (for patients with cirrhosis)
Study: 20404773
Drug: Weekly newsletter
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly newsletter (comparison group)
Study: 26711162
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy (NRT)
Study: 19887866
Drug: Capecitabine combination
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine combination chemotherapy (36% of patients, median starting dose 987 mg/m² b.i.d.)
Study: 11113398
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use
Study: 2885203
Drug: Acrivastine 4
Normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acrivastine 4 mg with alcohol 32 ml
Study: 25823907
Drug: 4-week buprenorphine
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-week buprenorphine taper
Study: 20192896
Drug: Sodium thiosulfate
Normalized name: Sodium Thiosulfate
DrugBank: Thiosulfuric acid (DB09499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium thiosulfate (STS) infusion
Study: 25193157
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol 25 micrograms every 2 hours for a maximum of 12 doses or until active labor commences
Study: 6128546
Drug: Albumin infusion
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin infusion
Study: 6380205
Drug: Bromhexine (Bisolvon)
Normalized name: bromhexine
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine (Bisolvon) 48 mg daily for 3 weeks
Study: 11979153
Drug: Gadodiamide at
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadodiamide at doses of 0.1 and 0.3 mmol/kg
Study: 19441606
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone acetonide aqueous nasal spray (TAA AQ), 110 microg once daily
Study: 16492208
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g) therapy for 2 days prior to re-testing
Study: 24681810
Drug: Quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quetiapine XR (400-800 mg/day)
Study: 23786762
Drug: Low-fat yoghurt
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat yoghurt with 1.9 g/d plant stanols as esters
Study: 12972102
Drug: MC-1 treatment
Normalized name: MC-1
DrugBank: MC-1 (DB05315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC-1 treatment
Study: 8335204
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Heme arginate + Tin protoporphyrin)
Study: 20973316
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (50 g as slurry with 250 ml of water)
Study: 15692125
Drug: Nimodipine 90
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 90 mg/d
Study: 25968968
Drug: Home intervention
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home intervention system (HIS, OPTILOGG(®)) with a tablet computer and weight scale
Study: 11122832
Drug: Antibody-drug conjugates
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibody-drug conjugates and immunotoxins
Study: 21783387
Drug: Low-dose Flutamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Flutamide
Study: 2252531
Drug: Patients in
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in remission (after stopping treatment)
Study: 8052871
Drug: Carboplatin 300
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin 300 mg/m2 day I, etoposide 140 mg/m2 days 1 through 3, and vincristine 1.4 mg/m2 days 1, 8, and 15 (CEV)
Study: 10764680
Drug: Peroral estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peroral estradiol valerate (2 mg/d)
Study: 12890374
Drug: Compressed air-driven
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compressed air-driven beta(2)-agonist therapy (Berotec)
Study: 30098049
Drug: Anticholinergic exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticholinergic exposure (defined by four methods for each of four anticholinergic scales: Anticholinergic Drug Scale, Anticholinergic Cognitive Burden, Anticholinergic Risk Scale, the Durán list)
Study: 2467136
Drug: Amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 mg daily
Study: 24879757
Drug: Zilpaterol hydrochloride
Normalized name: zilpaterol hydrochloride
DrugBank: Zilpaterol (DB11479)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilpaterol hydrochloride (ZH; 8.3 mg/kg of DM for 20 d with 3‐d withdrawal)
Study: 6210661
Drug: Intravenous mezlocillin
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mezlocillin (16 g/day)
Study: 30390065
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (Syntocinon®, Novartis; 10 puffs = 20 international units per treatment)
Study: 10235086
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg/day
Study: 30518334
Drug: Oral Fosfomycin-Trometamol
Normalized name: trometamol
DrugBank: Tromethamine (DB03754)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Fosfomycin-Trometamol
Study: 22360134
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) pre-seasonal regimen: 5,000 AU/week for 10 weeks/year for 2 years (Group 2)
Study: 732468
Drug: Whole-gut irrigation
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-gut irrigation with antibiotics (neomycin-bacitracin-clindamycin)
Study: 24088534
Drug: BCG plus
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG plus single-dose rifampicin (SDR)
Study: 26712979
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TA) 20 mg/kg diluted to 25 cc with normal saline (Group T)
Study: 15365537
Drug: Telithromycin 800
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telithromycin 800 mg once daily for 5 days
Study: 20811918
Drug: No lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No lidocaine spray and ETTs lubricated with normal saline (Group C)
Study: 12633548
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with perindopril (4 mg daily) and indapamide (at physician's discretion)
Study: 3894129
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment or CSII (Continuous Subcutaneous Insulin Infusion)
Study: 3840743
Drug: Formulation N
Normalized name: N-6022
DrugBank: N-6022 (DB12206)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation N (higher plasma fenofibrate level)
Study: 3840743
Drug: Formulation R
Normalized name: Formulation R
DrugBank: Hydrogenated palm kernel oil (DB11144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation R (lower plasma fenofibrate level)
Study: 27835765
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100U/mL (Gla-100)
Study: 15321699
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C co-infusion
Study: 11257395
Drug: Adjuvant active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant active specific immunotherapy
Study: 21911741
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20,000 IU vitamin D(3) twice weekly for 6 months)
Study: 18515735
Drug: Upfront zoledronic
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Upfront zoledronic acid (4 mg intravenously every 6 months)
Study: 2511743
Drug: Sustained-release diltiazem
Normalized name: diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release diltiazem 180 mg twice daily
Study: 8115311
Drug: Isradipine plain
Normalized name: Isradipine
DrugBank: Isradipine (DB00270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isradipine plain formulation (2.5 mg twice daily)
Study: 10510878
Drug: Trimebutine maleate
Normalized name: Trimebutine maleate
DrugBank: Trimebutine (DB09089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine maleate (oral treatment for three weeks)
Study: 1857516
Drug: Intravaginal 1
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravaginal 1 mg Gemeprost
Study: 24683783
Drug: Intranasal midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intranasal midazolam spray
Study: 26019183
Drug: Low-dose THC
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose THC (2.9%) without alcohol
Study: 11864862
Drug: Dietary magnesium
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary magnesium intake of 320 mg/d (recommended dietary allowance)
Study: 9327093
Drug: Naltrexone hydrochloride
Normalized name: Naltrexone Hydrochloride
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone hydrochloride (NTX) 2 mg/kg
Study: 8847044
Drug: G-CSF therapy
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF therapy
Study: 19327467
Drug: Nafamostat mesylate
Normalized name: mesylate
DrugBank: Nafamostat (DB12598)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Nafamostat mesylate (20 mg) with 5% dextrose solution
Study: 19493959
Drug: Mirtazapine treatment
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine treatment for 8 weeks
Study: 9129083
Drug: Granulocyte colony-stimulating
Normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulocyte colony-stimulating factor (G-CSF), daily treatment over a 14-day period.
Study: 21560266
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (1 mg, pressurized metered dose inhaler)
Study: 15910512
Drug: AR-R15896AR 350
Normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AR-R15896AR 350 mg
Study: 25896352
Drug: Liraglutide treatment
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide treatment for 10 weeks
Study: 9014018
Drug: Biological markers
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological markers (serum GGT, ASAT, MCV, urate levels)
Study: 7964484
Drug: T cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T cell lines from treatment-resistant Lyme arthritis
Study: 14635010
Drug: IFN-alpha 2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IFN-alpha 2b 3 MU/day for 24 weeks, followed by 3 MU x 3/week for 24 weeks plus ribavirin 1-1.2 g/day for 48 weeks
Study: 12869379
Drug: 2-week oral
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week oral treatment with 3 x 5 mg/day terbutaline
Study: 25078053
Drug: Traditional protocol
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional protocol using clomiphene citrate (CC) 100 mg/day for patients who failed the 50 mg/day treatment in the previous cycle.
Study: 2101781
Drug: Oral captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral captopril 15 min before thrombolysis (37 patients)
Study: 9516063
Drug: Galanin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Galanin infusion (8 microg/Kg/h) in patients with active acromegaly (group II)